6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
prescribing O
information O
: O
* O
Vision B-OSE_Labeled_AE
Loss I-OSE_Labeled_AE
[ O
see O
BOXED O
WARNING O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Magnetic B-OSE_Labeled_AE
Resonance I-OSE_Labeled_AE
Imaging I-OSE_Labeled_AE
( I-OSE_Labeled_AE
MRI I-OSE_Labeled_AE
) I-OSE_Labeled_AE
Abnormalities I-OSE_Labeled_AE
in O
Infants O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Neurotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Suicidal B-OSE_Labeled_AE
Behavior I-OSE_Labeled_AE
and O
Ideation O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Withdrawal B-NonOSE_AE
of O
Antiepileptic O
Drugs O
( O
AEDs O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Anemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Somnolence B-OSE_Labeled_AE
and O
Fatigue B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Edema B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
EXCERPT O
: O
Refractory O
Complex O
Partial O
Seizures O
Most O
common O
adverse O
reactions O
in O
controlled O
studies O
include O
: O
* O
Adults O
> O
16 O
years O
of O
age O
( O
change O
of O
> O
=5 O
% O
over O
placebo O
) O
: O
in O
addition O
to O
permanent O
vision O
loss O
, O
fatigue O
, O
somnolence O
, O
nystagmus O
, O
tremor O
, O
vision O
blurred O
, O
memory O
impairment O
, O
weight O
gain O
, O
arthralgia O
, O
abnormal O
coordination O
, O
and O
confusional O
state O
( O
6.1 O
) O
* O
Pediatrics O
10 O
to O
16 O
years O
of O
age O
( O
change O
of O
> O
=5 O
% O
over O
placebo O
) O
: O
increased O
weight O
, O
upper O
respiratory O
tract O
infection O
, O
tremor O
, O
fatigue O
, O
aggression O
and O
diplopia O
( O
6.1 O
) O
Infantile O
Spasms O
( O
incidence O
> O
5 O
% O
) O
* O
Somnolence O
, O
bronchitis O
, O
ear O
infection O
, O
and O
otitis O
media O
acute O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Lundbeck O
at O
1-800-455-1141 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Adverse O
Reactions O
in O
U O
. O

S O
. O

and O
Primary O
Non-U O
. O

S O
. O

Clinical O
Studies O
In O
U.S O
. O
and O
primary O
non-U.S O
. O
clinical O
studies O
of O
4,079 O
SABRIL O
treated O
patients O
, O
the O
most O
commonly O
observed O
( O
> O
=5 O
% O
) O
adverse O
reactions O
associated O
with O
the O
use O
of O
SABRIL O
in O
combination O
with O
other O
AEDs O
were O
headache B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
convulsion B-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
visual B-OSE_Labeled_AE
field I-OSE_Labeled_AE
defect I-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
coordination B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
influenza B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
. O

The O
adverse O
reactions O
most O
commonly O
associated O
with O
SABRIL O
treatment O
discontinuation O
in O
> O
=1 O
% O
of O
patients O
were O
convulsion B-OSE_Labeled_AE
and O
depression B-OSE_Labeled_AE
. O

In O
patients O
with O
infantile B-Not_AE_Candidate
spasms I-Not_AE_Candidate
, O
the O
adverse O
reactions O
most O
commonly O
associated O
with O
SABRIL O
treatment O
discontinuation O
in O
> O
=1 O
% O
of O
patients O
were O
infections B-OSE_Labeled_AE
, O
status B-OSE_Labeled_AE
epilepticus I-OSE_Labeled_AE
, O
developmental B-OSE_Labeled_AE
coordination I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
hypotonia B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
and O
insomnia B-OSE_Labeled_AE
. O

Most O
Common O
Adverse O
Reactions O
in O
Controlled O
Clinical O
Trials O
Refractory B-Not_AE_Candidate
C I-Not_AE_Candidate
omplex I-Not_AE_Candidate
Partial I-Not_AE_Candidate
Seizures I-Not_AE_Candidate
Adults O
Table O
5 O
lists O
the O
treatment O
emergent O
adverse O
reactions O
that O
occurred O
in O
> O
=2 O
% O
and O
more O
than O
one O
patient O
per O
SABRIL O
treated O
group O
and O
that O
occurred O
more O
frequently O
than O
in O
placebo O
patients O
from O
2 O
U.S O
. O
add-on O
clinical O
studies O
of O
refractory B-Not_AE_Candidate
CPS I-Not_AE_Candidate
in O
adults O
. O

Table O
5 O
. O

Treatment O
Emergent O
Adverse O
Reactions O
Occurring O
in O
> O
=2 O
% O
and O
More O
than O
One O
Patient O
per O
SABRIL-Treated O
Group O
and O
More O
Frequently O
than O
in O
Placebo O
Patients O
( O
Studies O
024 O
and O
025 O
) O
SABRIL O
dosage O
( O
mg/day O
) O
Body O
System O
Adverse O
Reaction O
3000 O
[ O
N=134 O
] O
% O
6000 O
[ O
N=43 O
] O
% O
Placebo O
[ O
N=135 O
] O
% O
Ear B-NonOSE_AE
Disorders I-NonOSE_AE
Tinnitus B-OSE_Labeled_AE
2 O
0 O
1 O
Vertigo B-OSE_Labeled_AE
2 O
5 O
1 O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
13 O
16 O
5 O
Diplopia B-OSE_Labeled_AE
7 O
16 O
3 O
Asthenopia B-OSE_Labeled_AE
2 O
2 O
0 O
Eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
0 O
5 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhoea B-OSE_Labeled_AE
10 O
16 O
7 O
Nausea B-OSE_Labeled_AE
10 O
2 O
8 O
Vomiting B-OSE_Labeled_AE
7 O
9 O
6 O
Constipation B-OSE_Labeled_AE
8 O
5 O
3 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
5 O
5 O
1 O
Dyspepsia B-OSE_Labeled_AE
4 O
5 O
3 O
Stomach B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
4 O
2 O
1 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
3 O
2 O
1 O
Toothache B-OSE_Labeled_AE
2 O
5 O
2 O
Abdominal B-OSE_Labeled_AE
distension I-OSE_Labeled_AE
2 O
0 O
1 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
23 O
40 O
16 O
Gait B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
6 O
12 O
7 O
Asthenia B-OSE_Labeled_AE
5 O
7 O
1 O
Oedema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
5 O
7 O
1 O
Fever B-OSE_Labeled_AE
4 O
7 O
3 O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
5 O
1 O
Thirst B-OSE_Labeled_AE
2 O
0 O
0 O
Malaise B-OSE_Labeled_AE
0 O
5 O
0 O
Infections B-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
14 O
9 O
10 O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
7 O
9 O
6 O
Influenza B-OSE_Labeled_AE
5 O
7 O
4 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
4 O
5 O
0 O
Bronchitis B-OSE_Labeled_AE
0 O
5 O
1 O
Injury B-NonOSE_AE
Contusion B-OSE_Labeled_AE
3 O
5 O
2 O
Joint B-OSE_Labeled_AE
sprain I-OSE_Labeled_AE
1 O
2 O
1 O
Muscle B-OSE_Labeled_AE
strain I-OSE_Labeled_AE
1 O
2 O
1 O
Wound B-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
0 O
2 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Increased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
1 O
5 O
1 O
Weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
6 O
14 O
3 O
Musculoskeletal B-NonOSE_AE
Disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
10 O
5 O
3 O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
4 O
7 O
2 O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
6 O
2 O
4 O
Myalgia B-OSE_Labeled_AE
3 O
5 O
1 O
Muscle B-OSE_Labeled_AE
twitching I-OSE_Labeled_AE
1 O
9 O
1 O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
3 O
0 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
33 O
26 O
31 O
Somnolence B-OSE_Labeled_AE
22 O
26 O
13 O
Dizziness B-OSE_Labeled_AE
24 O
26 O
17 O
Nystagmus B-OSE_Labeled_AE
13 O
19 O
9 O
Tremor B-OSE_Labeled_AE
15 O
16 O
8 O
Memory B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
7 O
16 O
3 O
Coordination B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
7 O
16 O
2 O
Disturbance B-OSE_Labeled_AE
in I-OSE_Labeled_AE
attention I-OSE_Labeled_AE
9 O
0 O
1 O
Sensory B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
4 O
7 O
2 O
Hyporeflexia B-OSE_Labeled_AE
4 O
5 O
1 O
Paraesthesia B-OSE_Labeled_AE
7 O
2 O
1 O
Lethargy B-OSE_Labeled_AE
4 O
7 O
2 O
Hyperreflexia B-OSE_Labeled_AE
4 O
2 O
3 O
Hypoaesthesia B-OSE_Labeled_AE
4 O
5 O
1 O
Sedation B-OSE_Labeled_AE
4 O
0 O
0 O
Status B-OSE_Labeled_AE
epilepticus I-OSE_Labeled_AE
2 O
5 O
0 O
Dysarthria B-OSE_Labeled_AE
2 O
2 O
1 O
Postictal B-OSE_Labeled_AE
state I-OSE_Labeled_AE
2 O
0 O
1 O
Sensory B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
0 O
5 O
0 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Irritability B-OSE_Labeled_AE
7 O
23 O
7 O
Depression B-OSE_Labeled_AE
6 O
14 O
3 O
Confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
4 O
14 O
1 O
Anxiety B-OSE_Labeled_AE
4 O
0 O
3 O
Depressed B-OSE_Labeled_AE
mood I-OSE_Labeled_AE
5 O
0 O
1 O
Thinking B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
3 O
7 O
0 O
Abnormal B-OSE_Labeled_AE
behaviour I-OSE_Labeled_AE
3 O
5 O
1 O
Expressive B-OSE_Labeled_AE
language I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
1 O
7 O
1 O
Nervousness B-OSE_Labeled_AE
2 O
5 O
2 O
Abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
1 O
5 O
1 O
Reproductive B-NonOSE_AE
System I-NonOSE_AE
Dysmenorrhoea B-OSE_Labeled_AE
9 O
5 O
3 O
Erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
0 O
5 O
0 O
Respiratory B-NonOSE_AE
and I-NonOSE_AE
Thoracic I-NonOSE_AE
Disorders I-NonOSE_AE
Pharyngolaryngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
7 O
14 O
5 O
Cough B-OSE_Labeled_AE
2 O
14 O
7 O
Pulmonary B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
0 O
5 O
1 O
Sinus B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
6 O
2 O
1 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
4 O
5 O
4 O
Pediatrics O
10 O
to O
16 O
years O
of O
age O
Table O
6 O
lists O
adverse O
reactions O
from O
controlled O
clinical O
studies O
of O
pediatric O
patients O
receiving O
SABRIL O
or O
placebo O
as O
add-on O
therapy O
for O
refractory O
complex B-Not_AE_Candidate
partial I-Not_AE_Candidate
seizures I-Not_AE_Candidate
. O

Adverse O
reactions O
that O
are O
listed O
occurred O
in O
at O
least O
2 O
% O
of O
SABRIL O
treated O
patients O
and O
more O
frequently O
than O
placebo O
. O

The O
median O
SABRIL O
dose O
was O
49.4 O
mg/kg O
, O
( O
range O
of O
8.0 O
- O
105.9 O
mg/kg O
) O
. O

Table O
6 O
. O

Treatment-Emergent O
Adverse O
Reactions O
Reported O
by O
> O
=2 O
% O
of O
Pediatric O
CPS O
Patients O
( O
10 O
to O
16 O
years O
of O
age O
) O
Treated O
with O
SABRIL O
and O
Higher O
than O
Placebo O
Body O
System O
Adverse O
Reaction O
All O
SABRIL O
[ O
N=109 O
] O
% O
Placebo O
[ O
N=46 O
] O
% O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
Diplopia B-OSE_Labeled_AE
5 O
0 O
Vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
3 O
0 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Diarrhoea B-OSE_Labeled_AE
6 O
2 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
3 O
0 O
Constipation B-OSE_Labeled_AE
3 O
2 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
9 O
4 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
10 O
4 O
Influenza B-OSE_Labeled_AE
6 O
2 O
Otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
6 O
2 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
17 O
2 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Somnolence B-OSE_Labeled_AE
6 O
2 O
Tremor B-OSE_Labeled_AE
6 O
0 O
Nystagmus B-OSE_Labeled_AE
5 O
2 O
Psychomotor B-OSE_Labeled_AE
hyperactivity I-OSE_Labeled_AE
4 O
2 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
6 O
2 O
Aggression B-OSE_Labeled_AE
5 O
0 O
Disorientation B-OSE_Labeled_AE
4 O
0 O
Reproduction B-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
Dysmenorrhea B-OSE_Labeled_AE
3 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Acne B-OSE_Labeled_AE
3 O
0 O
Infantile B-Not_AE_Candidate
Spasms I-Not_AE_Candidate
In O
a O
randomized O
, O
placebo-controlled O
IS O
study O
with O
a O
5 O
day O
double-blind O
treatment O
phase O
( O
n=40 O
) O
, O
the O
adverse O
events O
reported O
by O
> O
5 O
% O
of O
patients O
receiving O
SABRIL O
and O
that O
occurred O
more O
frequently O
than O
in O
placebo O
patients O
, O
were O
somnolence B-OSE_Labeled_AE
( O
SABRIL O
45 O
% O
, O
placebo O
30 O
% O
) O
, O
bronchitis B-OSE_Labeled_AE
( O
SABRIL O
30 O
% O
, O
placebo O
15 O
% O
) O
, O
ear B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
SABRIL O
10 O
% O
, O
placebo O
5 O
% O
) O
, O
and O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
acute I-OSE_Labeled_AE
SABRIL O
10 O
% O
, O
placebo O
0 O
% O
) O
. O

In O
a O
dose O
response O
study O
of O
low-dose O
( O
18-36 O
mg/kg/day O
) O
versus O
high-dose O
( O
100-148 O
mg/kg/day O
) O
vigabatrin O
, O
no O
clear O
correlation O
between O
dose O
and O
incidence O
of O
adverse O
events O
was O
observed O
. O

The O
treatment O
emergent O
adverse O
reactions O
( O
> O
=5 O
% O
in O
either O
dose O
group O
) O
are O
summarized O
in O
Table O
7 O
. O

Table O
7 O
. O

Treatment O
Emergent O
Adverse O
Reactions O
Occurring O
in O
> O
=5 O
% O
of O
Infantile O
Spasms O
Patients O
SABRILLow O
Dose O
SABRIL O
High O
Dose O
Body O
System O
Adverse O
Reaction O
[ O
N=114 O
] O
% O
[ O
N=108 O
] O
% O
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
( O
other O
than O
field O
or O
acuity O
changes O
) O
Strabismus B-OSE_Labeled_AE
5 O
5 O
Conjunctivitis B-OSE_Labeled_AE
5 O
2 O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Vomiting B-OSE_Labeled_AE
14 O
20 O
Constipation B-OSE_Labeled_AE
14 O
12 O
Diarrhea B-OSE_Labeled_AE
13 O
12 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fever B-OSE_Labeled_AE
29 O
19 O
Infections B-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
51 O
46 O
Otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
44 O
30 O
Viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
20 O
19 O
Pneumonia B-OSE_Labeled_AE
13 O
11 O
Candidiasis B-OSE_Labeled_AE
8 O
3 O
Ear B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
7 O
14 O
Gastroenteritis B-OSE_Labeled_AE
viral I-OSE_Labeled_AE
6 O
5 O
Sinusitis B-OSE_Labeled_AE
5 O
9 O
Urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
5 O
6 O
Influenza B-OSE_Labeled_AE
5 O
3 O
Croup B-OSE_Labeled_AE
infectious I-OSE_Labeled_AE
5 O
1 O
Metabolism B-NonOSE_AE
& I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
9 O
7 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Sedation B-OSE_Labeled_AE
19 O
17 O
Somnolence B-OSE_Labeled_AE
17 O
19 O
Status B-OSE_Labeled_AE
epilepticus I-OSE_Labeled_AE
6 O
4 O
Lethargy B-OSE_Labeled_AE
5 O
7 O
Convulsion B-OSE_Labeled_AE
4 O
7 O
Hypotonia B-OSE_Labeled_AE
4 O
6 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Irritability B-OSE_Labeled_AE
16 O
23 O
Insomnia B-OSE_Labeled_AE
10 O
12 O
Respiratory B-NonOSE_AE
Disorders I-NonOSE_AE
Nasal B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
13 O
4 O
Cough B-OSE_Labeled_AE
3 O
8 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
8 O
11 O
6.2 O
Post O
Marketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
reported O
during O
post O
approval O
use O
of O
SABRIL O
worldwide O
. O

All O
adverse O
reactions O
that O
are O
not O
listed O
above O
as O
adverse O
reactions O
reported O
in O
clinical O
trials O
, O
that O
are O
not O
relatively O
common O
in O
the O
population O
and O
are O
not O
too O
vague O
to O
be O
useful O
are O
listed O
in O
this O
section O
. O

These O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
; O
therefore O
, O
it O
is O
not O
possible O
to O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Adverse O
reactions O
are O
categorized O
by O
system O
organ O
class O
. O

Birth B-NonOSE_AE
Defects I-NonOSE_AE
: O
Congenital B-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
defects I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
external I-OSE_Labeled_AE
ear I-OSE_Labeled_AE
anomaly I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
hemangioma I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
hydronephrosis I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
male I-OSE_Labeled_AE
genital I-OSE_Labeled_AE
malformation I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
oral I-OSE_Labeled_AE
malformation I-OSE_Labeled_AE
, O
congenital B-OSE_Labeled_AE
vesicoureteric I-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
, O
dentofacial O
anomaly O
, O
dysmorphism O
, O
fetal O
anticonvulsant O
syndrome O
, O
hamartomas O
, O
hip O
dysplasia O
, O
limb O
malformation O
, O
limb O
reduction O
defect O
, O
low O
set O
ears O
, O
renal O
aplasia O
, O
retinitis O
pigmentosa O
, O
supernumerary O
nipple O
, O
talipes O
Ear B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Deafness B-OSE_Labeled_AE
Endocrine B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Delayed B-OSE_Labeled_AE
puberty I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Developmental B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
, O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
malignant B-OSE_Labeled_AE
hyperthermia I-OSE_Labeled_AE
, O
multi B-OSE_Labeled_AE
- I-OSE_Labeled_AE
organ I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Cholestasis B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Dystonia B-OSE_Labeled_AE
, O
encephalopathy B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
hypotonia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasticity I-OSE_Labeled_AE
, O
myoclonus B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Acute B-OSE_Labeled_AE
psychosis I-OSE_Labeled_AE
, O
apathy B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
hypomania B-OSE_Labeled_AE
, O
neonatal B-OSE_Labeled_AE
agitation I-OSE_Labeled_AE
, O
psychotic B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Laryngeal B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
stridor B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Angioedema B-OSE_Labeled_AE
, O
maculo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
papular I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
SJS O
) O
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
( O
TEN O
) O

